Neurol. pro Praxi, 2006; 1: 36-42

Nová antiepileptika v klinické praxi

doc. MUDr. Robert Kuba, Ph.D.
I. neurologická klinika LF MU a FN u sv. Anny Brno

Za posledních 15 let bylo v epileptologii do klinické praxe zavedeno mnoho „nových antiepileptik“. Některé z těchto léků se používají pouze ve velmi omezených indikacích, zejména z důvodů nežádoucích účinků (felbamát a vigabatrin). V současné době je v České republice registrováno 6 „nových antiepileptik“, která v epileptologii nalezla širšího využití. Jedná se o lamotrigin, gabapentin, topiramát, tiagabin, levetiracetam a pregabalin. Některé z těchto nových antiepileptik jsou již registrována v České republice i pro další „neepileptologické“ a dokonce „neneurologické“ indikace, jako například lamotrigin v léčbě bipolární poruchy, topiramát v prevenci migrény, gabapentin a pregabalin v léčbě neuropatické bolesti. Článek podává přehled o indikacích zmíněných antiepileptik v epileptologii.

Keywords: Klíčová slova: epilepsie, nová antiepileptika, terapie.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kuba R. Nová antiepileptika v klinické praxi. Neurol. praxi. 2006;7(1):36-42.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin Add-on Treatment: A randomized, double - blind, placebo - controlled, dose - respons study in adults with partial seizures.
    2. Baulac M, Spiegel K, Lee CM, Barrett JA. Long-term seizure freedom in patients with partial seizures treated with add-on pregabalin: update of an ongoing analysis of four open-label trials. Epilepsia 2004; 45(Suppl. 3): S154.
    3. Beydoun A, Fakhoury T, Nasreddine W, Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 1998; 39: 188-193. Go to original source... Go to PubMed...
    4. Beydoun AA, Uthmann BM, Ramsay RE, et al. Pregabalin add - on trial: double - blind multicenter study in patients with partial epilepsy. Epilepsia 2000; 41(Suppl.7): 253-254.
    5. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 55: 1758. Go to original source... Go to PubMed...
    6. Cunnington MC. The International Lamotrigine Pregnancy Registry Update for the Epilepsy Fundation. Epilepsia 2004; 45: 1468. Go to original source... Go to PubMed...
    7. Dodson WE, Kamin M, Kraut L, Olson WH, Wu S. Topiramate titration to response: Analysis of individualized therapy study (TRAITS). Ann Pharmacol 2003; 37: 615-620. Go to original source... Go to PubMed...
    8. French JA, Kugler AR, Robbins JL, et al. Dose - response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631-1637. Go to original source... Go to PubMed...
    9. Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. Epilepsia 1998; 39: 26-29. Go to original source... Go to PubMed...
    10. Glauser TA, Gauer LJ, Chen L and LEV N159 Pediatric Study Group. Multicenter, double - blind, placebo controlled trial of adjunctive levetiracetam therapy in pediatric patients with refractory partial epilepsy. Epilepsia 2004; 45(Suppl. 7): S186. Go to original source...
    11. Guerrini R, Carpay J, Grošelj J, Van Oene J, Schreiner A, Lahaye M, Schwallen S on behalf of the TOP - INT - 51 investigators group. Topiramate monotherapy as broad - spectrum antiepileptic drug in a naturalistic clinical setting. Seizure 2005; 14: 371-380. Go to original source... Go to PubMed...
    12. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsa 1998; 39: 508-512. Go to original source... Go to PubMed...
    13. Koepp MJ, Edwards M, Collins J, Farrel F, Smith S. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005; 46(1625-1632). Go to original source... Go to PubMed...
    14. Kuba R, Novotná I, Brázdil M, Křížová J, Tyrlíková I, Rektor I. Topiramát v dlouhodobé terapii farmakorezistentní epilepsie. Neurol pro praxi 2004; 5: 231-234.
    15. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002; 11: 77-84. Go to original source... Go to PubMed...
    16. Lynch BA, Lambeng, Nocka R, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101: 9861-9866. Go to original source... Go to PubMed...
    17. Mohanraj R, Parker PG, Stephen LJ, Brodie MJ. Levetiracetam in refractory epilepsy: a prospective obsevational study. Seizure 2005; 14: 23-27. Go to original source... Go to PubMed...
    18. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S, for the EPMN 105 Study group. Topiramate, carbamazepine and valproate monotherapy: double - blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-175. Go to original source... Go to PubMed...
    19. Ribacoba MR, Salas PX. Efficacy and tolerability of long-term topiramate in drug resistant epilepsy in adults. Rev Neurol 2002; 34: 101-105.
    20. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose - frequency study. Arch Neurol 1997; 54: 595-601. Go to original source... Go to PubMed...
    21. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-respons trial. Arch Neurol 1998; 55: 56-62. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.